Newsfeeds - Spark Newswire

3 minute read

Regulus Therapeutics Reports Successful Completion Of Pre-Investigational New Drug Meeting With FDA For RGLS8429

Today, 10:45 PM

Company remains on track to submit IND and initiate Phase 1 study in second quarter 2022 Company to include evaluation of treatment impact on slowing cystic kidney expansion SAN DIEGO, Jan. 20, 2022 /PRNewswire/

RGLS

4 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 10:45 PM

On Wednesday, 41 stocks made new 52-week lows.

AVGR

32 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 10:45 PM

On Thursday, 615 stocks hit new 52-week lows.

AAOI

4 minute read

Stocks Hitting New 52-Week Lows Today

By Benzinga Insights

Today, 10:45 PM

On Monday morning, 60 companies achieved new lows for the year.

AGIL

1 minute read

Regulus Therapeutics Q3 EPS $(0.10) Misses $(0.08) Estimate

By Benzinga Newsdesk

Today, 10:45 PM

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 150 percent decrease over losses of $(0.04) per share from

RGLS

18 minute read

Earnings Scheduled For November 10, 2021

By Benzinga Insights

Today, 10:45 PM

Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.

AACG

1 minute read

Regulus Therapeutics Granted US Patent ‘Methods for treatment of polycystic kidney disease’

By Bill Haddad

Today, 10:45 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=4848&f=G&l=50&d=PTXT&p=97&S1=20211109&OS=20211109&RS=20211109

RGLS

4 minute read

How The Future Looks For Last Week’s Biggest Losers: Futu, Regulus Therapeutics And More

By Melanie Schaffer

Today, 10:45 PM

Last week, the five biggest stock market losers declined between about 36% and 26%. Below is a look at each stock and what they may have in the cards going forward.

FUTU

4 minute read

50 Biggest Movers From Yesterday

By Lisa Levin

Today, 10:45 PM

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target.

ADGI

3 minute read

Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher

By Lisa Levin

Today, 10:45 PM

Toward the end of trading Wednesday, the Dow traded up 0.06% to 34,398.86 while the NASDAQ rose 0.70% to 14,566.72. The S&P also rose, gaining 0.31% to 4,364.35.

CRXT